Promising vaccines for treating glioblastoma

References

• Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017 Nov 6;19(suppl_5):v1–v88. PubMed PMID: 29117289; PubMed Central PMCID: PMCPMC5693142.
   PubMed Web of Science ®Google Scholar
• Dandy WE. Removal of right cerebral hemisphere for certain tumors with hemiplegia: preliminary report. J Am Med Assoc. 1928;90(11):823–825.
   Google Scholar
• Stupp R, Mason WP, van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987–996. PubMed PMID: 15758009.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May;10(5):459–466. PubMed PMID: 19269895.
   PubMed Web of Science ®Google Scholar
• Desai R, Suryadevara CM, Batich KA, et al. Emerging immunotherapies for glioblastoma. Expert Opin Emerg Drugs. 2016 Jun;21(2):133–145. PubMed PMID: 27223671; PubMed Central PMCID: PMCPMC4915370.
   PubMed Web of Science ®Google Scholar
• Weller M, Roth P, Preusser M, et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol. 2017 Jun;13(6):363–374. PubMed PMID: 28497804.
   PubMed Web of Science ®Google Scholar
• Crotty S. A brief history of T cell help to B cells [Perspective]. Nat Rev Immunol. 2015;15:185. 02/13/online.
   PubMed Web of Science ®Google Scholar
• De Silva NS, Klein U. Dynamics of B cells in germinal centres [Review Article]. Nat Rev Immunol. 2015;15:137. 02/06/online.
   PubMed Web of Science ®Google Scholar
• MacLennan Ian CM, Toellner KM, Cunningham Adam F, et al. Extrafollicular antibody responses. Immunological Reviews. 2003 08 01;194(1):8–18.
   PubMed Web of Science ®Google Scholar
• Krogsgaard M, Davis MM. How T cells ‘see’ antigen [review article]. Nat Immunol. 2005 02 18;6:239.
   PubMed Web of Science ®Google Scholar
• Shastri N, Cardinaud S, Schwab Susan R, et al. All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen‐processing pathway. Immunological Reviews. 2005 10 01;207(1):31–41. .
   PubMedGoogle Scholar
• Joffre OP, Segura E, Savina A, et al. Cross-presentation by dendritic cells [review article]. Nat Rev Immunol. 2012;12:557. 07/13/online.
   PubMed Web of Science ®Google Scholar
• Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Reviews Immunol. 2014 12 13;14(1):24–35. . PubMed PMID: PMC4032067.
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012 Sep;12(9):623–635. . PubMed PMID: 22903150.
   PubMed Web of Science ®Google Scholar
• Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. Brain Behav Immun. 2017 Feb;60:1–12. PubMed PMID: 26995317.
   PubMed Web of Science ®Google Scholar
• Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 2012 Dec;33(12):579–589. . PubMed PMID: 22926201.
   PubMed Web of Science ®Google Scholar
• Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015 Jul 16;523(7560):337–341. PubMed PMID: 26030524; PubMed Central PMCID: PMCPMC4506234.
   PubMed Web of Science ®Google Scholar
• Nduom EK, Weller M, Heimberger AB. Immunosuppressive mechanisms in glioblastoma. Neuro Oncol. 2015 Nov;17 Suppl 7:vii9–vii14. PubMed PMID: 26516226; PubMed Central PMCID: PMCPMC4625890.
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017 Mar 13;31(3):326–341. . PubMed PMID: 28292436; PubMed Central PMCID: PMCPMC5424263.
   PubMed Web of Science ®Google Scholar
• Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012 Mar 1;72(5):1081–1091. PubMed PMID: 22237626.
   PubMed Web of Science ®Google Scholar
• Warshakoon HJ, Hood JD, Kimbrell MR, et al. Potential adjuvantic properties of innate immune stimuli. Hum Vaccin. 2009 Jun;5(6):381–394. PubMed PMID: 19270494.
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997 Dec;27(12):3135–3142. PubMed PMID: 9464798.
   PubMed Web of Science ®Google Scholar
• Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004 Sep 1;64(17):5934–5937. PubMed PMID: 15342370.
   PubMed Web of Science ®Google Scholar
• Mitchell DA, Batich KA, Gunn MD, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015 Mar 19;519(7543):366–369. PubMed PMID: 25762141; PubMed Central PMCID: PMCPMC4510871.
   PubMed Web of Science ®Google Scholar
• Reap EA, Suryadevara CM, Batich KA, et al. Dendritic cells enhance polyfunctionality of adoptively transferred T cells that target cytomegalovirus in glioblastoma. Cancer Res. 2018 Jan 1;78(1):256–264. PubMed PMID: 29093005; PubMed Central PMCID: PMCPMC5754236.
   PubMed Web of Science ®Google Scholar
• Shirota H, Petrenko L, Hong C, et al. Potential of transfected muscle cells to contribute to DNA vaccine immunogenicity. J Immunol. 2007 Jul 1;179(1):329–336. PubMed PMID: 17579053.
   PubMed Web of Science ®Google Scholar
• Kranz LM, Diken M, Haas H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016 Jun 16;534(7607):396–401. PubMed PMID: 27281205.
   PubMed Web of Science ®Google Scholar
• Belmans J, Van Woensel M, Creyns B, et al. Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival. Sci Rep. 2017 Oct 24;7(1):13902. 10.1038/s41598-017-12584-0. PubMed PMID: 29066810; PubMed Central PMCID: PMCPMC5654749.
   PubMedGoogle Scholar
• Prins RM, Wang X, Soto H, et al. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother. 2013 Feb;36(2):152–157. PubMed PMID: 23377664; PubMed Central PMCID: PMCPMC3568250.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Ashley DM, et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system. Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10399–10404. PubMed PMID: 8816812; PubMed Central PMCID: PMCPMC38396.
   PubMed Web of Science ®Google Scholar
• Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991 May 10;252(5007):854–856. PubMed PMID: 1851332.
   PubMed Web of Science ®Google Scholar
• Chiocca EA. Oncolytic viruses. Nat Rev Cancer. 2002 Dec;2(12):938–950. . PubMed PMID: 12459732.
   PubMed Web of Science ®Google Scholar
• Guo ZS, Liu Z, Kowalsky S, et al. Oncolytic immunotherapy: conceptual Evolution, Current Strategies, and Future Perspectives. Front Immunol. 2017;8:555. PubMed PMID: 28555136; PubMed Central PMCID: PMCPMC5430078.
   PubMed Web of Science ®Google Scholar
• De Munck J, Binks A, McNeish IA, et al. Oncolytic virus-induced cell death and immunity: a match made in heaven? J Leukoc Biol. 2017 Sep;102(3):631–643. PubMed PMID: 28720686.
   PubMed Web of Science ®Google Scholar
• Prestwich RJ, Harrington KJ, Pandha HS, et al. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther. 2008 Oct;8(10):1581–1588. PubMed PMID: 18925850; PubMed Central PMCID: PMCPMC2729453.
   PubMed Web of Science ®Google Scholar
• Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7727–7731. PubMed PMID: 8052651; PubMed Central PMCID: PMCPMC44475.
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Suki D, Yang D, et al. The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med. 2005 Oct 19;3:38. PubMed PMID: 16236164; PubMed Central PMCID: PMCPMC1298339.
   PubMed Web of Science ®Google Scholar
• Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 1997 Jan 31;272(5):2927–2935. PubMed PMID: 9006938.
   PubMed Web of Science ®Google Scholar
• Ekstrand AJ, Longo N, Hamid ML, et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene. 1994 Aug;9(8):2313–2320. PubMed PMID: 8036013.
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003 Sep 15;9(11):4247–4254. PubMed PMID: 14519652.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009 Oct 8;10:2773–2779. doi: 10.1158/1535-7163.MCT-09-0124. PubMed PMID: 19825799; PubMed Central PMCID: PMCPMC2991139.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011 Mar;13(3):324–333. PubMed PMID: 21149254; PubMed Central PMCID: PMCPMC3064599.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Schuster J, et al. IMCT-08 ReACT: long-term survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. Neuro Oncol. 2015;17(suppl_5):v109–v109.
   Google Scholar
• Weller M, Butowski N, Tran DD, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1373–1385. PubMed PMID: 28844499.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010 Nov 1;28(31):4722–4729. PubMed PMID: 20921459; PubMed Central PMCID: PMCPMC3020702.
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765–773. PubMed PMID: 19228619; PubMed Central PMCID: PMCPMC2820383.
   PubMed Web of Science ®Google Scholar
• Platten M, Bunse L, Riehl D, et al. Vaccine strategies in gliomas. Curr Treat Options Neurol. 2018 Mar 28;20(5):11. 10.1007/s11940-018-0498-1. PubMed PMID: 29594595.
   PubMed Web of Science ®Google Scholar
• Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009 Oct 1;15(19):6002–6007. 10.1158/1078-0432.CCR-09-0715. PubMed PMID: 19755387.
   PubMed Web of Science ®Google Scholar
• Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012 Feb 15;483(7390):479–483. PubMed PMID: 22343889; PubMed Central PMCID: PMCPMC3351699.
   PubMed Web of Science ®Google Scholar
• Bunse L, Schumacher T, Sahm F, et al. Proximity ligation assay evaluates IDH1R132H presentation in gliomas. J Clin Invest. 2015 Feb;125(2):593–606. PubMed PMID: 25555220; PubMed Central PMCID: PMCPMC4319432.
   PubMed Web of Science ®Google Scholar
• Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014 Aug 21;512(7514):324–327. PubMed PMID: 25043048.
   PubMed Web of Science ®Google Scholar
• Kajiwara Y, Yamasaki F, Hama S, et al. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer. 2003 Feb 15;97(4):1077–1083. PubMed PMID: 12569609.
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19;17(1):98–110. PubMed PMID: 20129251; PubMed Central PMCID: PMCPMC2818769.
   PubMed Web of Science ®Google Scholar
• Fenstermaker RA, Ciesielski MJ, Qiu J, et al. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother. 2016 Nov;65(11):1339–1352. 10.1007/s00262-016-1890-x. PubMed PMID: 27576783; PubMed Central PMCID: PMCPMC5069322.
   PubMed Web of Science ®Google Scholar
• Polyzoidis S, Ashkan K. DCVax(R)-L–developed by Northwest Biotherapeutics. PubMed PMID: 25483653; PubMed Central PMCID: PMCPMC4514134 Hum Vaccin Immunother. 2014;1011:3139–3145.
   PubMed Web of Science ®Google Scholar
• Liau LM, Ashkan K, Tran DD, et al. First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 May 29;16(1):142. PubMed PMID: 29843811; PubMed Central PMCID: PMCPMC5975654.
   PubMedGoogle Scholar
• Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013 Jan;62(1):125–135. PubMed PMID: 22847020; PubMed Central PMCID: PMCPMC3541928.
   PubMed Web of Science ®Google Scholar
• Wen P, Reardon D, Phuphanich S, et al. AT-60A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 2 TRIAL OF DENDRITIC CELL (DC) VACCINE ICT-107 FOLLOWING STANDARD TREATMENT IN NEWLY DIAGNOSED PATIENTS WITH GBM. Neuro-Oncology. 2014;16(Suppl 5):v22.
   Google Scholar
• Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol. 2008 Feb;10(1):10–18. 10.1215/15228517-2007-035. PubMed PMID: 17951512; PubMed Central PMCID: PMCPMC2600830.
   PubMed Web of Science ®Google Scholar
• Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002 Jun 15;62(12):3347–3350. PubMed PMID: 12067971.
   PubMed Web of Science ®Google Scholar
• Baumgarten P, Michaelis M, Rothweiler F, et al. Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics. Neuro Oncol. 2014 Nov;16(11):1469–1477. PubMed PMID: 25155358; PubMed Central PMCID: PMCPMC4201076.
   PubMed Web of Science ®Google Scholar
• Batich KA, Reap EA, Archer GE, et al. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clin Cancer Res. 2017 Apr 15;23(8):1898–1909. PubMed PMID: 28411277; PubMed Central PMCID: PMCPMC5559300.
   PubMed Web of Science ®Google Scholar
• Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014 Jun 20;344(6190):1396–1401. PubMed PMID: 24925914; PubMed Central PMCID: PMCPMC4123637.
   PubMed Web of Science ®Google Scholar
• Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009–4014. PubMed PMID: 23412337; PubMed Central PMCID: PMCPMC3593922
   PubMed Web of Science ®Google Scholar
• Rampling R, Peoples S, Mulholland PJ, et al. A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clin Cancer Res. 2016 Oct 1;22(19):4776–4785. PubMed PMID: 27225692; PubMed Central PMCID: PMCPMC5026298.
   PubMed Web of Science ®Google Scholar
• Wollmann G, Ozduman K, van Den Pol AN. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J. 2012 Jan-Feb;18(1):69–81. . PubMed PMID: 22290260; PubMed Central PMCID: PMCPMC3632333.
   PubMed Web of Science ®Google Scholar
• Foreman PM, Friedman GK, Cassady KA, et al. Oncolytic virotherapy for the treatment of malignant glioma. Neurotherapeutics. 2017 Apr;14(2):333–344. 10.1007/s13311-017-0516-0. PubMed PMID: 28265902; PubMed Central PMCID: PMCPMC5398989.
   PubMed Web of Science ®Google Scholar
• Conrady CD, Drevets DA, Carr DJ. Herpes simplex type I (HSV-1) infection of the nervous system: is an immune response a good thing?J Neuroimmunol. 2010 Mar 30;220(1–2):1–9. . PubMed PMID: 19819030; PubMed Central PMCID: PMCPMC2835842.
   PubMed Web of Science ®Google Scholar
• Grandi P, Peruzzi P, Reinhart B, et al. Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother. 2009 Apr;9(4):505–517. PubMed PMID: 19344302; PubMed Central PMCID: PMCPMC3219506.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015 Sep 1;33(25):2780–2788. PubMed PMID: 26014293.
   PubMed Web of Science ®Google Scholar
• Perez OD, Logg CR, Hiraoka K, et al. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther. 2012 Sep;20(9):1689–1698. PubMed PMID: 22547150; PubMed Central PMCID: PMCPMC3437576.
   PubMed Web of Science ®Google Scholar
• Mitchell LA, Lopez Espinoza F, Mendoza D, et al. Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. Neuro Oncol. 2017 Jul 1;19(7):930–939. PubMed PMID: 28387849; PubMed Central PMCID: PMCPMC5570153.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Landolfi J, Hogan DJ, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med. 2016 Jun 1;8(341):341ra75. PubMed PMID: 27252174.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Landolfi J, Vogelbaum MA, et al. Durable complete responses in some recurrent high grade glioma patients treated with Toca 511 & Toca FC. Neuro Oncol. 2018 May 12 PubMed PMID: 29762717. DOI:10.1093/neuonc/noy075.
   Web of Science ®Google Scholar
• Castro MG, Candolfi M, Wilson TJ, et al. Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther. 2014 Sep;14(9):1241–1257. PubMed PMID: 24773178; PubMed Central PMCID: PMCPMC4127140.
   PubMed Web of Science ®Google Scholar
• King GD, Muhammad AK, Larocque D, et al. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol Ther. 2011 Oct;19(10):1793–1801. PubMed PMID: 21505426; PubMed Central PMCID: PMCPMC3188756.
   PubMed Web of Science ®Google Scholar
• Curtin JF, Liu N, Candolfi M, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009 Jan 13;6(1):e10. PubMed PMID: 19143470; PubMed Central PMCID: PMCPMC2621261.
   PubMed Web of Science ®Google Scholar
• King GD, Muhammad AK, Curtin JF, et al. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol. 2008 Feb;10(1):19–31. 10.1215/15228517-2007-045. PubMed PMID: 18079358; PubMed Central PMCID: PMCPMC2600834.
   PubMed Web of Science ®Google Scholar
• Holm GH, Zurney J, Tumilasci V, et al. Retinoic acid-inducible gene-I and interferon-beta promoter stimulator-1 augment proapoptotic responses following mammalian reovirus infection via interferon regulatory factor-3. J Biol Chem. 2007 Jul 27;282(30):21953–21961. PubMed PMID: 17540767.
   PubMed Web of Science ®Google Scholar
• Wilcox ME, Yang W, Senger D, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst. 2001 Jun 20;93(12):903–912. PubMed PMID: 11416111.
   PubMedGoogle Scholar
• Prestwich RJ, Errington F, Ilett EJ, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res. 2008 Nov 15;14(22):7358–7366. PubMed PMID: 19010851; PubMed Central PMCID: PMCPMC2701231.
   PubMed Web of Science ®Google Scholar
• Samson A, Scott KJ, Taggart D, et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci Transl Med. 2018 Jan 3;10(422). PubMed PMID: 29298869.
   PubMed Web of Science ®Google Scholar
• Jiang H, Gomez-Manzano C, Lang FF, et al. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther. 2009 Oct;9(5):422–427. PubMed PMID: 19860656; PubMed Central PMCID: PMCPMC2935304.
   PubMed Web of Science ®Google Scholar
• Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000 Jan 6;19(1):2–12. PubMed PMID: 10644974.
   PubMed Web of Science ®Google Scholar
• Fueyo J, Alemany R, Gomez-Manzano C, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003 May 7;95(9):652–660. PubMed PMID: 12734316.
   PubMed Web of Science ®Google Scholar
• Jiang H, Clise-Dwyer K, Ruisaard KE, et al. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One. 2014;9(5):e97407. PubMed PMID: 24827739; PubMed Central PMCID: PMCPMC4020829.
   PubMed Web of Science ®Google Scholar
• Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018 May 10;36(14):1419–1427. PubMed PMID: 29432077.
   PubMed Web of Science ®Google Scholar
• Gromeier M, Alexander L, Wimmer E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2370–2375. PubMed PMID: 8637880; PubMed Central PMCID: PMCPMC39803.
   PubMed Web of Science ®Google Scholar
• Ochiai H, Campbell SA, Archer GE, et al. Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Clin Cancer Res. 2006 Feb 15;12(4):1349–1354. PubMed PMID: 16489093.
   PubMed Web of Science ®Google Scholar
• Brown MC, Holl EK, Boczkowski D, et al. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci Transl Med. 2017 Sep 20;9(408). PubMed PMID: 28931654.
   Web of Science ®Google Scholar
• Desjardins A, Gromeier M, Herndon JE 2nd. et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018 Jul 12;379(2):150–161. PubMed PMID: 29943666; PubMed Central PMCID: PMCPMC6065102.
   PubMed Web of Science ®Google Scholar
• Han J, Alvarez-Breckenridge CA, Wang QE, et al. TGF-beta signaling and its targeting for glioma treatment. Am J Cancer Res. 2015;5(3):945–955. PubMed PMID: 26045979; PubMed Central PMCID: PMCPMC4449428.
   PubMed Web of Science ®Google Scholar
• Mbongue JC, Nicholas DA, Torrez TW, et al. The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity. Vaccines (Basel). 2015 Sep 10;3(3):703–729. PubMed PMID: 26378585; PubMed Central PMCID: PMCPMC4586474.
   PubMed Web of Science ®Google Scholar
• Jordan JT, Sun W, Hussain SF, et al. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother. 2008 Jan;57(1):123–131. PubMed PMID: 17522861.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T cells: how do they suppress immune responses? Int Immunol. 2009;21(10):1105–1111.
   PubMed Web of Science ®Google Scholar
• Mitchell DA, Cui X, Schmittling RJ, et al. Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 2011 Sep 15;118(11):3003–3012. PubMed PMID: 21768296; PubMed Central PMCID: PMCPMC3175779.
   PubMed Web of Science ®Google Scholar
• Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013 Aug 26;210(9):1695–1710. PubMed PMID: 23897981; PubMed Central PMCID: PMCPMC3754863.
   PubMed Web of Science ®Google Scholar
• Sotomayor EM, Borrello I, Tubb E, et al. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476–11481. PubMed PMID: 10500201; PubMed Central PMCID: PMCPMC18058.
   PubMed Web of Science ®Google Scholar
• Giles AJ, Hutchinson MND, Sonnemann HM, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018 Jun 11;6(1):51. 10.1186/s40425-018-0371-5. PubMed PMID: 29891009; PubMed Central PMCID: PMCPMC5996496.
   PubMedGoogle Scholar
• Hinrichs CS, Palmer DC, Rosenberg SA, et al. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J Immunother. 2005 Nov-Dec;28(6):517–524. PubMed PMID: 16224268; PubMed Central PMCID: PMCPMC1484506.
   PubMed Web of Science ®Google Scholar
• Darmon I, Morisse MC, Coutte A, et al. Temozolomide and bevacizumab induction before chemoradiotherapy in patients with bulky glioblastoma and/or with severe neurological impairment. J Cancer. 2017;8(8):1417–1424. PubMed PMID: 28638456; PubMed Central PMCID: PMCPMC5479247.
   PubMed Web of Science ®Google Scholar
• Thomas AA, Fisher JL, Hampton TH, et al. Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma. Cancer Immunol Immunother. 2017 Mar;66(3):379–389. PubMed PMID: 27942839
   PubMed Web of Science ®Google Scholar
• Osada T, Chong G, Tansik R, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother. 2008 Aug;57(8):1115–1124. PubMed PMID: 18193223; PubMed Central PMCID: PMCPMC4110970.
   PubMed Web of Science ®Google Scholar
• Sanchez-Perez L, Suryadevara CM, Choi BD, et al. Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. Oncoimmunology. 2014;3(7):e944054. PubMed PMID: 25610727; PubMed Central PMCID: PMCPMC4292586.
   PubMed Web of Science ®Google Scholar
• Sanchez-Perez LA, Choi BD, Archer GE, et al. Myeloablative temozolomide enhances CD8(+) T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One. 2013;8(3):e59082. PubMed PMID: 23527092; PubMed Central PMCID: PMCPMC3601076.
   PubMed Web of Science ®Google Scholar
• Litterman AJ, Zellmer DM, Grinnen KL, et al. Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol. 2013 Jun 15;190(12):6259–6268. PubMed PMID: 23686484; PubMed Central PMCID: PMCPMC3680135
   PubMed Web of Science ®Google Scholar
• Pellegatta S, Eoli M, Cuccarini V, et al. Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8(+) T cell activation in the presence of adjuvant temozolomide. Oncoimmunology. 2018;7(4):e1412901. PubMed PMID: 29632727; PubMed Central PMCID: PMCPMC5889286.
   PubMed Web of Science ®Google Scholar
• Pessina S, Cantini G, Kapetis D, et al. The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma. Oncoimmunology. 2016 May;5(5):e1108513. PubMed PMID: 27467914; PubMed Central PMCID: PMCPMC4910710.
   PubMed Web of Science ®Google Scholar
• Sanchez-Perez L, Choi BD, Reap EA, et al. BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunol Immunother. 2013 Jun;62(6):983–987. PubMed PMID: 23591978; PubMed Central PMCID: PMCPMC3665719.
   PubMed Web of Science ®Google Scholar
• Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005 Nov;25(21):9543–9553. PubMed PMID: 16227604; PubMed Central PMCID: PMCPMC1265804.
   PubMed Web of Science ®Google Scholar
• Han S, Zhang C, Li Q, et al. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer. 2014 May 13;110(10):2560–2568. PubMed PMID: 24691423; PubMed Central PMCID: PMCPMC4021514.
   PubMed Web of Science ®Google Scholar
• Woroniecka K, Chongsathidkiet P, Ke R, et al. T cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res. 2018 Feb 7. 10.1158/1078-0432.CCR-17-1846. PubMed PMID: 29437767.
   Web of Science ®Google Scholar
• Nduom EK, Wei J, Yaghi NK, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016 Feb;18(2):195–205. PubMed PMID: 26323609; PubMed Central PMCID: PMCPMC4724183.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509–2520. PubMed PMID: 26028255; PubMed Central PMCID: PMCPMC4481136.
   PubMed Web of Science ®Google Scholar
• Reardon D, Omuro A, Brandes A, et al. OS10. 3 Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: checkMate 143. Neuro-Oncology. 2017;19(suppl_3):iii21–iii21.
   Google Scholar
• Wasiuk A, Testa J, Weidlick J, et al. CD27-mediated regulatory T cell depletion and effector T cell costimulation both contribute to antitumor efficacy. J Immunol. 2017 Dec 15;199(12):4110–4123. PubMed PMID: 29109120; PubMed Central PMCID: PMCPMC5713498.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017 Dec 21;377(25):2500–2501. PubMed PMID: 29262275.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013 Aug 22;500(7463):415–421. PubMed PMID: 23945592; PubMed Central PMCID: PMCPMC3776390.
   PubMed Web of Science ®Google Scholar
• Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014 Jan 10;343(6167):189–193. PubMed PMID: 24336570; PubMed Central PMCID: PMCPMC3998672.
   PubMed Web of Science ®Google Scholar
• Anandappa AJ, Keskin DB, Hu Z, et al. Detecting neoepitope-specific intra-tumoral T cell responses in a glioblastoma patient treated with personal neoantigen vaccine. The Journal of Immunology. 2018;200 (1Supplement):181.11-181.11
   Google Scholar